The Readout Loud – Details, episodes & analysis

Podcast details

Technical and general information from the podcast's RSS feed.

The Readout Loud

STAT

Business

Frequency: 1 episode/7d. Total Eps: 344

STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.

Site

RSS

Apple

Data updated on 04/07/2026

Recent rankings

Latest chart positions across Apple Podcasts and Spotify rankings.

Apple Podcasts

🇩🇪 Germany - Business
12/02/2025
#91
🇩🇪 Germany - Business
11/02/2025
#71
🇩🇪 Germany - Business
10/02/2025
#58
🇩🇪 Germany - Business
09/02/2025
#86

Spotify

No recent rankings available

Shared links between episodes and podcasts

Links found in episode descriptions and other podcasts that share them.

See all

No links shared by this podcast

RSS feed quality and score

Technical evaluation of the podcast's RSS feed quality and structure.

See all

RSS feed quality

To improve

Score global : 43%

Publication history

Monthly episode publishing history over the past years.

Year

Latest published episodes

Recent episodes with titles, durations, and descriptions.

See all

340: Crisis in CRISPR world, RFK Jr.'s promises, and a novel non-opioid pain drug

Thursday, February 6, 2025 • Duration 34:45

We bring on our colleague Jason Mast to discuss the dramatic downturn in the once-swaggering field of CRISPR gene editing. We also talk about the advancement of RFK Jr.'s nomination to be HHS secretary, the latest pharma earnings, and the approval of a non-opioid pain drug from Vertex Pharmaceuticals.

Read moreCollapse

339: RFK Jr.'s confirmation hearings, MASH drugs, and a controversial obesity ad

Thursday, January 30, 2025 • Duration 34:29

Our colleague Rachel Cohrs Zhang joins us to break down RFK Jr.’s confirmation hearings, including some contentious questions about vaccines and autism from Sens. Bill Cassidy (R-La.) and Bernie Sanders (I-Vt.). But first, we chat about Akero Therapeutics and the results reported this week from a study of its experimental drug that showed, for the first time, reversal of cirrhosis in patients with severe MASH. We critique that Hims & Hers commercial. And lastly, we talk about a new fund from biotech VC Curie.Bio and the money it’s invested in a still-stealthy gene therapy company trying to tackle ALS.

Read moreCollapse

338: Chinese biotechs, a WHO departure, and post-JPM thoughts

Thursday, January 23, 2025 • Duration 33:09

We go over our closing thoughts from the J.P. Morgan Healthcare Conference, including the chatter around Chinese drugs and a surprise run-in with a past cohost. Then, STAT's infectious disease reporter Helen Branswell joins us to explain the implications of Trump's decision to pull the U.S. out of the WHO.

Read moreCollapse

337: Eli Lilly CEO on Trump, obesity drugs, and a guidance miss

Wednesday, January 15, 2025 • Duration 58:47

We're live at the J.P Morgan Healthcare Conference in San Francisco! We bring on Eli Lilly CEO Dave Ricks for a wide-ranging conversation about his views on the incoming Trump administration, the effects of Medicare's drug price negotiation, Lilly's recent disappointing guidance, pricing of the company's obesity medication Zepbound, and more. We also discuss the latest news from the J.P. Morgan conference, including M&A deals, licensing of drugs from China, and the broader sentiment in the industry.

Read moreCollapse

336: Pharma's big patent cliff, more obesity fundraising, and a failed ALS study

Thursday, January 9, 2025 • Duration 33:21

We chat about how pharmaceutical companies are navigating a looming patent cliff. We also talk about yet another obesity startup and a failed study from Google’s secretive anti-aging company Calico.

335: A deep dive on Makary, Vertex's pain data, & 2025 predictions

Thursday, December 19, 2024 • Duration 33:43

STAT's FDA reporter Lizzy Lawrence joins us to discuss her profile of Marty Makary, Trump's nominee for FDA commissioner. Then, we discuss the results of Vertex's latest pain drug trial, the medication launches to watch in 2025, and present our burning questions for the biopharma industry.

Read moreCollapse

334: Pharma silence on RFK Jr. & parents trying to develop gene therapies for their children

Thursday, December 12, 2024 • Duration 34:30

Washington correspondent John Wilkerson joins to discuss why drugmakers have not lobbied against Robert F. Kennedy Jr.'s nomination to lead the Department of Health and Human Services, despite his repeated criticisms of the pharmaceutical industry. We also bring on our colleague Jason Mast to talk about the major hurdles in the field of gene therapy and how one father is trying to overcome them.

Read moreCollapse

333: An H5N1 bird flu update and talent scarcity in the radiopharma field

Thursday, December 5, 2024 • Duration 27:55

You might not be paying attention, or maybe you just hope it goes away. We’re referring to the serious bird flu outbreak that started a bit more than eight months ago. Well, bird flu is still here and the number of reported cases in people is growing. STAT’s infectious disease reporter Helen Branswell joins us for an update. But first, we break down the results from a GLP-1 showdown study that compared Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy. Allison shares her recent reporting on a talent shortage that is posing new challenges to the fast-growing radiopharmaceutical industry.

Read moreCollapse

332: Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner?

Thursday, November 21, 2024 • Duration 35:08

Atlas Venture Partner Bruce Booth joins the podcast to discuss his annual year in review report, the influence of China, and what the new Trump administration might mean for innovation. Adam and Allison also recap the latest news in the life sciences, including a new science chief at Pfizer, a new job for Ned Sharpless, and the ongoing presidential appointments.

Read moreCollapse

331: AbbVie’s stumble, Amgen’s tumble and more election fallout

Thursday, November 14, 2024 • Duration 30:16

Why are AbbVie executives feeling the M&A blues? What does it take to slice $12 billion from Amgen’s market value? And why are STAT’s D.C. correspondents working so hard? We talk about all that and more on this week’s episode of the “The Readout LOUD,” STAT’s biotech podcast. It’s a “Chatty Cathy” episode! Elaine, Allison and Adam lead off with a discussion about AbbVie’s M&A miscue following the failure of a closely followed schizophrenia drug. You’d hate us if obesity drugs weren’t mentioned, so we oblige with a tick-tock on what went down between Amgen and a Wall Street analyst who noted a possible safety issue with the obesity drug candidate MariTide.

Read moreCollapse

The Readout Loud – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify

The Readout Loud – Details, episodes & analysis

Podcast details

Recent rankings

Apple Podcasts

Spotify

Shared links between episodes and podcasts

RSS feed quality and score

Publication history

Latest published episodes

Similar podcasts and content

Related Shows Based on Content Similarities

Related Shows Based on Content Similarities

Apple Podcasts

Spotify